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Editorials
Pharmacists have been employed in UK 
general practice for many years. Their 
numbers are now expanding and their 
roles developing. Clinical pharmacists 
are expected to alleviate workload 
pressures on GPs. Notwithstanding the 
COVID-19 vaccination programme, a new 
Structured Medication Review (SMR) 
service has been introduced in Primary 
Care Networks (PCNs). The long term 
drivers are clear: addressing problematic 
polypharmacy in the NHS, reducing 
avoidable hospitalisations, and delivering 
better value from medicines spending.1 
SMRs are intended to improve the quality 
of prescribing, delivering improvements to 
patient care and outcomes. 
RAPID IMPLEMENTATION OF PCNs AND 
THE SMR
The roll-out of PCNs and the development 
of the SMR specification were both done at 
speed. Collaboration between GP practices 
to form PCNs under the Network Contract 
Directed Enhanced Service (DES) requires 
time and goodwill to build the relationships 
needed to manage clinical, organisational, 
and business interests collectively.2 Short 
timescales between policy statements, 
guidance, and expected implementation 
have jeopardised effective planning, adding 
to pressures on clinicians and services 
during the COVID-19 pandemic.  
SMRs were one of the first five DES 
specifications proposed, originally to 
be delivered to a range of patient priority 
groups from April 2020. In response to initial 
consultation, additional new PCN roles were 
added, including pharmacy technicians. The 
proposed SMR service was also simplified by 
reducing the number of target populations 
and allowing the volume of SMRs to be 
determined locally.3 COVID-19 planning 
then took centre stage and has interrupted 
implementation profoundly. Guidance issued 
in March 2020 stressed prioritising responses 
to the pandemic, thus delaying introduction 
of the SMR. Vaccination was identified as a 
workforce priority in early 2021.4  
The full SMR specification, first published 
shortly before its formal introduction in 
September 2020, included the wider offer 
of SMRs to patients who might benefit, 
subject to clinical pharmacist capacity.5 
New information (in an annex) expanded the 
scope of SMRs to include attention to the 
main public health behavioural risk factors 
of smoking, physical activity, diet and weight 
management, and alcohol, as well as falls 
prevention.5 Further amendments have been 
made since, including expanding the range 
of targeted potentially addictive medicines, 
specifying a minimum consultation duration 
of 30 minutes, and bringing children into 
scope.6 
Important changes with implications for 
the developing PCN clinical pharmacist role 
have thus been made at short notice, and a 
time when much of the NHS workforce has 
been focused on managing the pandemic. 
This raises questions about expectations, 
preparedness, and practice development.7 
SMR conduct is to be personalised, holistic, 
and conducted in line with the principles of 
shared decision making, attentive to health 
literacy, and likely to be largely delivered 
remotely for now.6 Newly recruited clinical 
pharmacists conducting SMRs are required 
to have, or be in training for, a prescribing 
qualification, and to have advanced 
assessment and history-taking skills.6 
Many are coming from the community 
pharmacy workforce where such skills are 
not a requirement. Since an initial 18-month 
training pathway (or equivalent) must first 
be completed, the SMR is being introduced 
when few are fully trained, and when training 
and supervision provision has been impacted 
by the pandemic.7 
In socioeconomically deprived areas 
where polypharmacy is more common and 
there are underserved populations, the SMR 
could represent an especially important 
innovation. Little information is provided 
in the DES that appreciates the nature of 
any distinct challenges posed, or how they 
may be addressed. This is for each PCN 
to determine. Similarly, content on how to 
incorporate brief advice for public health 
purposes in ways underpinned by shared 
decision-making principles is limited. In 
the case of alcohol, for example, alongside 
advice-giving, the annex notes the potential 
for interactions with medicines and the need 
for review, neither of which are congruent 
with the recommended form of brief advice. 
There is further work to be done in 
developing the service and monitoring 
implementation if SMRs are to make the 
kinds of contribution that are anticipated. 
Account must also be taken of what is known 
about the nature of the person-centred 
consultation skills possessed by the new 
clinical pharmacist workforce within primary 
care, and the strengths and limitations of the 
existing evidence.
SMR EVIDENCE
Pharmacist-led medicine reviews have 
an important role to play in improving 
prescribing safety.8 The original design of 
the SMR service and the subsequently made 
amendments have, however, engaged with 
research evidence in limited ways. National 
Institute for Health and Care Excellence 
(NICE) clinical guidelines for medicines 
optimisation9 are cited as the principal source 
of evidence for SMRs.5,6 Closer examination 
shows weaknesses in this evidence base. 
Most trials reviewed by NICE were of low 
to moderate quality and reported mixed 
findings for diverse outcomes in populations 
that do not resemble those identified as 
priorities for the SMR.9
There is a growing appreciation 
of the potential contribution of the 
expanded pharmacist role in primary 
care,10,11 and established GP practice 
pharmacists’ experience may facilitate 
SMR implementation in some practices. 
However, few studies investigate actual 
practice, such as how pharmacy work is 
routinely conducted,10 nor is there evidence 
to show that pharmacists possess skills in 
shared decision making as operationalised 
in general practice. Studies in community 
pharmacy and primary care identify a 
substantial gap between patient-centred 
consultation ideas encouraging patient-
generated problem solving and medicines 
review practice centred on information 
provision.12,13 In general practice, both 
GPs and pharmacists perceive a trade-off 
between being time efficient and involving 
the patient in making decisions about their 
medicines.14  
Incorporating public health brief advice 
generates questions about how the targets 
(for example, obesity) may be implicated in 
issues raised in medicines-focused work, 
such as in relation to adherence. Where 
it exists, available evidence supportive of 
pharmacists addressing these as standalone 
issues (for example, as adjuncts) is, at best, 
highly variable.15 Alcohol provides another 
instructive example. The SMR specification 
highlights the risks to patient safety from 
interactions with medicines.16 Recognition 
of the far reaching nature of the issues with 
which alcohol is implicated17 is a welcome 
first step in advancing thinking about 
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clinical approaches for both prevention and 
treatment of multimorbidity.18 Implicit in 
the SMR is a more advanced conception 
of prevention for alcohol than the narrow 
NHS Long Term Plan focus on dependent 
drinkers and averting their hospitalisation.19 
This could usefully become more explicit. 
Conceptualising alcohol as a drug20 fits 
with the core pharmaceutical role, 
meaning pharmacists may regard the SMR 
as a legitimate and important venue for 
addressing alcohol use in routine medicine 
consultations. Doing so could contribute 
to a strategic shift in how the NHS thinks 
about and manages the relationships 
between such behavioural risk factors, 
chronic conditions, and care provided. It 
potentially offers a smarter way forward 
than promoting widespread dissemination 
of crude advice, with disappointing uptake.21 
THE FUTURE OF SMRs
The challenges facing the new clinical 
pharmacist workforce were already 
formidable, and have been made more so 
by the COVID-19 pandemic.2 The balance 
of forces between centralised contractual 
implementation and locally tailored 
innovations will play out in different ways 
in different places. The active involvement 
of pharmacists in taking on clearer 
leadership roles in medicines review practice 
developments is paramount for the potential 
of SMRs to be realised. This requires ongoing 
evaluation of how pharmacists develop their 
emerging roles in primary care and acquire 
more advanced person-centred clinical skills 
in delivering SMRs for diverse and complex 
needs. General practice and the quality of 
the service received by patients can benefit, 
with patients helped to use their medicines 
in ways that work better for them, improving 
population health as a result.  
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